Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

114.03
-1.2050-1.05%
Post-market: 114.950.9235+0.81%19:30 EDT
Volume:878.99K
Turnover:100.01M
Market Cap:12.33B
PE:251.35
High:115.98
Open:114.29
Low:111.94
Close:115.23
52wk High:126.38
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.91
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:17.46
PE(LYR):139.05

Loading ...

Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know

Benzinga Earnings
·
Jul 30

Movement Alert|Corcept Therapeutics Overnight Rise 20.02%, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance

Market Focus
·
Jul 30

Stock Track | Corcept Therapeutics Soars 25.20% in 24 Hours as Q2 Earnings Massively Beat, Guidance Raised

Stock Track
·
Jul 30

Corcept Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Stock Track | Corcept Therapeutics Soars 18.34% in After-Hours Trading After Q2 Earnings Massively Beat Estimates

Stock Track
·
Jul 30

Movement Alert|Corcept Therapeutics Rises 18.34% in After-Hours Trading, Q2 Earnings Significantly Beat Expectations

Market Focus
·
Jul 30

GUIDANCE: (CORT) Corcept Therapeutics Expects Full Year 2026 Revenue Range $1.1B - $1.2B, vs. FactSet Est of $999.5M

MT Newswires Live
·
Jul 30

Earnings Flash (CORT) Corcept Therapeutics Posts Q2 EPS $0.36, vs. FactSet Est of $0.02

MT Newswires Live
·
Jul 30

Corcept Therapeutics Q2 EPS USD 0.36

Reuters
·
Jul 30

Corcept Q2 FY26 Net Income Rises to $43 Million; Revenue Climbs 32% to $256.1 Million

Reuters
·
Jul 30

Corcept Therapeutics Q2 Revenue Estimates, Raises 2026 Outlook

Reuters
·
Jul 30

Corcept Therapeutics Q2 EPS $0.36 Beats $(0.00) Estimate, Sales $256.147M Beat $219.988M Estimate

Benzinga Earnings
·
Jul 30

Corcept Therapeutics is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jul 30

U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal

Reuters
·
Jul 29

Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $150 from $135

THOMSON REUTERS
·
Jul 29

Corcept Therapeutics Cut to Underperform from Peer Perform by Wolfe Research

Dow Jones
·
Jul 27

Top Growth Companies With Insider Ownership For July 2026

Simply Wall St.
·
Jul 27

Movement Alert|Corcept Therapeutics Rises 5.36% in Regular Trading, Cushing Syndrome NDA Resubmission and Earnings Expectations Boost Sentiment

Market Focus
·
Jul 24

Corcept Therapeutics to Announce Second Quarter Financial Results

Reuters
·
Jul 23

Corcept Therapeutics Schedules Second-quarter Results Conference Call

Reuters
·
Jul 23